The essential role of testosterone in hormonal male contraception

Testosterone: Action, Deficiency, Substitution, Fourth Edition

Volumn , Issue , 2012, Pages 470-493

  Nieschlag, Eberhard ^a   Behre, Hermann M ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84931431833     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003353.023     Document Type: Chapter

References (114)

1. Alvarez-Sanchez F, Faundes A, Brache V, Leon P (1977) Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception15:635-648
2. Amory JK, Leonard TW, Page ST, O’Toole E, McKenna MJ, Bremner WJ (2009) Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: singledose pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol64:641-645
3. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM (1999) A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotrophin levels with fewer metabolic effects than higher dosage combinations. J Androl20:407-414
4. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh- Bennink HJ, Bremner WJ (2000) Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and highdensity lipoprotein suppression. Fertil Steril74:707-714
5. Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, Matsumoto AM (2005) Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl26:405-413
6. Anderson RA, Baird DT (1997) Progress towards a male pill. IPPF Med Bull31:1-5
7. Anderson RA, Van Der Spuy ZM, Dada OA, Tregoning SK, Zinn PM, Adeniji OA, Fakoya TA, Smith KB, Baird DT (2002a) Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum Reprod17:2869-2877
8. Anderson RA, Kinniburgh D, Baird DT (2002b) Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocr Metab87:3640-3649
9. Aribarg A, Sukcharoen N, Chanprasit Y, Ngeamvijawat J, Kriangsinyos R (1996) Suppression of spermatogenesis by testosterone enanthate in Thai men. J Med Assoc Thai79:624-629
10. Arysad, KM (1993) Sperm function in Indonesian men treated with testosterone enanthate. Int J Androl16:355-361
11. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocr Metab81:757-762
12. Behre HM, Nashan D, Hubert W, Nieschlag E (1992) Depot gonadotropin-releasing hormone agonist blunts the androgeninduced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocr Metab74:84-90
13. Behre HM, Böckers A, Schlingheider A, Nieschlag E (1994) Sustained suppression of serum LH, FSH and testosterone and increase of highdensity lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix over 8 days in normal men. Clin Endocr40:241-248
14. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocr Metab80:2394-2403
15. Behre HM, Kliesch S, Lemcke B, Nieschlag E (2001) Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by 19-nortestosterone alone in normal men. Hum Reprod16:2570-2577
16. Bhasin S, Berman N, Swerdloff RS (1994) Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl15:386-391
17. Boccon-Gibod L, van der Meulen E, Persson BE (2011) An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol3:127-140
18. Brady BM, Walton M, Hollow N, Kicman AT, Baird DT, Anderson RA (2004) Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod19:2658-2667
19. Brenner PF, Mishell DR Jr, Bernstein GS, Ortiz A (1977) Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive. Contraception15:679-691
20. Büchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre HM, Nieschlag E (1999) Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocr Metab84:1244-1249
21. Cao J, Yuan J, Jin W (1996) Clinical trial of an anti-fertility method with testosterone enanthate in normal men. Chung Hua I Hsueh Tsa Chih76:335-337
22. CONRAD (2011) Male Hormonal Contraceptive Trial Ending Early: Innovative Study is a Collaboration of WHO and CONRAD, April 22, 2011. Available at: http://www.conrad.org/news-pressreleases-63.html (accessed Jan 20, 2012)
23. Cooper TG, Yeung CH (2010) Pharmacological approaches to male contraception. In: Nieschlag E, Behre HM, Nieschlag S (eds) Andrology. Male Reproductive Health and Dysfunction, 3rd edn. Springer-Verlag, Berlin, pp 589-599
24. Djerassi C, Miramontes L, Rosenkranz G, Sonheimer F (1954) Steroids LIV. Synthesis of 19-nor-17aethinyltestosterone and 19-nor-17amethyltestosterone. J Am Chem Soc76:4092-4094
25. Ersheng G, Cuihong L, Youlun G, Lamei L, Changhai H (1999) Inhibiting effects of sino-implant plus testosterone undecanoate on spermatogenesis in Chinese men. Reprod Contracept10:98-105
26. Faundes A, Brache V, Leon P, Schmidt F, Alvarez-Sanchez F (1981) Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg). Int J Androl4:235-245
27. Fogh M, Corker CS, Hunter WM, McLean H, Philip J, Schon G, Skakkebaek NE (1979) The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men. Acta Endocrinol91:545
28. Fogh M, Corker CS, McLean H (1980) Clinical trial with levonorgestrel and testosterone enanthate for male fertility control. Acta Endocrinol95:251-257
29. Frick J, Bartsch G, Weiske WH (1977) The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose. Contraception15:669-677
30. Frick J, Danner C, Kunit G, Joos H, Kohle R (1982) Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate. Int J Androl5:246-252
31. GawGonzaloIT, SwerdloffRS, NelsonAL, Clevenger B, Garcia R, Berman N, Wang C (2002) Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocr Metab87:3562-3572
32. Glasier A (2010) Acceptability of contraception for men: a review. Contraception82:453-450
33. Glasier AF, Anakwe R, Everington D, Martin CW, van der Spuy Z, Cheng L, Ho PC, Anderson RA (2000) Would women trust their partners to use a male pill? Hum Reprod15:646-649
34. Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF (2007) Steroid hormones for contraception in men. Cochrane Database Syst Rev 18:CD004316
35. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, Bo L, Xiong C, Wang X, Liu X, Peng L, Yao K (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab94:1910-1915
36. Gu YQ, Wang X-H, Xu D, Peng L, Cheng L-F, Huang M-K, Huang Z-J, Zhang G-Y (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocr Metab88:562-568
37. Gu YQ, Tong JS, Ma DZ, Wang XH, Yuan D, Tang WH, Bremner WJ (2004) Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J Clin Endocrinol Metab89:2254-2262
38. Guerin JF, Rollet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl11:187-199
39. Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yang J, Yang PJ, Gao ES (2004) Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl25:720-727
40. Hair WM, Kitteridge K, Wu FCW (1999) A new male contraceptive pill/patch combination - oral desogestrel and transdermal testosterone: suppression of gonadotropins and spermatogenesis in men. In: The Endocrine Society's 81st Annual Meeting; 1999 June 12-15; San Diego, CA, USA; Poster P3-374
41. HandelsmanDJ, Conway AJ, BoylanLM (1992) Suppression of human spermatogenesis by testosterone implants. J Clin Endocr Metab75:1326-1332
42. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA (1996) Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab81:4113-4121
43. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod20:549-556
44. Kamischke A, Nieschlag E (2004) Progress towards hormonal male contraception.Trends Pharmacol Sci25:49-57
45. Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E (2000a) Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol53:43-52
46. Kamischke A, Diebäcker J, Nieschlag E (2000b) Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin Endocrinol53:351-358
47. Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocr Metab86:303-309
48. Kamischke A, Heuermann T, Krüger K, von Eckardstein S, Schellschmidt I, Rübig A, Nieschlag E (2002) An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocr Metab87:530-539
49. Kinniburgh D, Anderson RA, Baird DT (2001) Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl22:88-95
50. Kinniburgh D, Zhu H, Cheng L, Kicman AT, Baird DT, Anderson RA (2002) Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod17:1490-1501
51. Knuth UA, Behre, HM, Belkien L, Bents H, Nieschlag E (1985) Clinical trial of 19-nortestosteronehexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril44:814-821
52. KnuthUA, YeungCH, Nieschlag E (1989) Combination of 19-nortestosteronehexyoxyphenylpropionate (Anadur) and depot-medroxyprogesteroneacetate (Clinovir) for male contraception. Fertil Steril51:1011-1018
53. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C; Hormonal Male Contraception Summit Group (2006) Rate, extent and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet367:1412-1420
54. Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT (2000) Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod15:637-645
55. McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5a-reductase inhibitor, for male hormonal contraception. Contraception62:73-78
56. McLachlan RI, O’Donnell L, Stanton PG, Balourdos G, Frydenberg M, DeKretser DM, Robertson DM (2002) Effects of testosterone enanthate plus medroxyprogesterone acetate on semen quality, reproductive hormones and germ cell populations in normal young men. J Clin Endocrinol Metab87:546-556
57. Melo JF, Coutinho EM (1977) Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. Contraception15:627-634
58. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvala L, Motta R, Pavani A, Capelli M, Flamigni C (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocr Metab81:3018-3023
59. Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C (1997) An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril68:844-850
60. Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C (1998) Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod13:1225-1229
61. Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM (2002a) Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl23:684-690
62. Meriggiola MC, Bremner WJ, Costantino A, Bertaccini A, Morselli-Labate AM, Huebler D, Kaufmann G, Oettel M, Flamigni C (2002b) Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab87:2107-2113
63. Meriggiola MC, Costantino A, Cerpolini S, Bremner WJ, Huebler D, Morselli-Labate AM, Kirsch B, Bertaccini A, Pelusi C, Pelusi G (2003) Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab88:5818-5826
64. Meriggiola MC, Costantino A, Saad F, D’Emidio L, Morselli Labate AM, BertacciniA, BremnerWJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G (2005) Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab90:2005-2014
65. Misro MM, Chaki SP, Kaushik MC, Nandan D (2009) Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy andreversibility studies in rats. Contraception79:488-497
66. Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J (1980) Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in man. Contraception21:393
67. Mommers E, Kersemaeker WM, Elliesen J, Kepers M, Apter D, Behre HM, Beynon J, Bouloux PM, Costantino A, Gerbershagen HP, Gronlund L, Heger-Mahn D, Huhtaniemi I, Koldewihn EL, Lange C, Lindenberg S, Meriggiola MC, Meuleman E, Mulder PFA, Nieschlag E, Perheentupa A, Solomon A, Väisälä L, Wu FC, Zitzmann M (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab93:2572-2580
68. Narula A, Gu Y-Q, O’Donnell L, Stanton PG, Robertson DM, McLachlan RI, Bremner WJ (2002) Variability in sperm suppression during testosterone administration to adult monkeys is related to follicle stimulating hormone suppression and not to intratesticular androgens. J Clin Endocrinol Metab87:3399-3406
69. Nieschlag E (1986) Reasons for abandoning immunization against FSH as an approach to male fertility regulation. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra J (eds) Male Contraception: Advances and Future Prospects. Harper & Row, Philadelphia, pp 395-400
70. Nieschlag E (2009) Male hormonal contraception: love's labour's lost? (Editorial) J Clin Endocrinol Metab94:1890-1892
71. Nieschlag E, Behre HM (1996) Hormonal male contraception: suppression of spermatogenesis with GnRH antagonists and testosterone. In: Filicori M, Flamigni C (eds) Treatment with GnRH Analogs: Controversies and Perspectives. Parthenon, London, pp 243-248
72. Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception18:607-614
73. Nieschlag E, Behre HM, Weinbauer GF (1992) Hormonal male contraception: a real chance? In: Nieschlag E, Habenicht UF (eds) Spermatogenesis - Fertilization - Contraception. Molecular, Cellular and Endocrine Events in Male Reproduction. Springer, Heidelberg, pp 477-501
74. Nieschlag E; 10th Summit Meeting Group (2007) 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. October 22-23, 2006. Contraception75:166-167
75. Nieschlag E, Nieschag S, Behre HM (eds) (2010) Andrology. Male Reproductive Health and Dysfunction, 3rd edn. Springer- Verlag, Berlin
76. Nieschlag E, Vorona E, Wenk M, Hemker AK, Kamischke A, Zitzmann M (2011) Hormonal male contraception in men with normal and subnormal semen parameters. Int J Androl34:556-567
77. Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ (2006) Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab91:4374-4380
78. Pangkahila W (1991) Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men. Int J Androl14:248-256
79. Patanelli DJ (ed) (1978) Hormonal Control of Male Fertility (Workshop Proceedings), NIH Publication No. 78-1097. US Department of Health, Education, and Welfare (NIH), Bethesda, MD
80. Pavlou SN, Wakefield G, Schlechter NL, Lindner J, Souza KH, Kamilaris TC, Konidaris S, Rivier JE, ValeWW, Toglia M (1989) Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. J Clin Endocrinol Metab73:1360-1369
81. Pavlou SN, Herodotou D, Curtain M, Minaretzis D (1994) Complete suppression of spermatogenesis by co-administration of a GnRH antagonist plus a physiologic dose of testosterone. In: Proceedings of the 76th Meeting of the Endocrine Society, Anaheim, CA, p 1324
82. Pöllänen P, Nikkanen V, Huhtaniemi I (2001) Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for malehormonal contraception. Int J Androl24:369-380
83. Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G, Christensen PD, Hull L, Swerdloff RS, Wang C (2006) Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl27:853-867
84. Reddy PR, Rao JM (1972) Reversible antifertility action of testosterone propionate in human males. Contraception5:295-301
85. Schearer SB, Alvarez-Sanches F, Anselmo G, Brenner P, Coutinho E, Lathen-Faundes A, Frick J, Heinild B, Johansson EDB (1978) Hormonal contraception for men. Int J Androl2 (Suppl 2):680-712
86. Schürmeyer T, Knuth UA, Belkien L, Nieschlag E (1984) Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet25:417-420
87. Singh S, Sedh G, Hussain R (2010) Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann41:241-250
88. Soufir JC, Meduri G, Ziyyat A (2011) Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod26:1708-1714
89. Srinath BR, Wickings EJ, Witting CH, Nieschlag E (1983) Active immunization with follicle stimulating hormone for fertility control: a 4 1/2-year study in male rhesus monkeys. Fertil Steril40:110-117
90. Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ (1998) Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocr Metab83:3527-3533
91. Turner L, Wishart S, Conway AJ, Liu PY, Forbes E, McLachlan RI, Handelsman DJ (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocr Metab88:4659-4667
92. von Eckardstein S, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E (2002) CAG repeat length in the androgen receptor gene and gonadotropin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol57:647-655
93. von Eckardstein S, Noé G, Brache V, Nieschlag E, Croxatto H, Alvarez F, Moo-Young A, Sivin I, Kumar N, Small M, Sundaram K (2003) A clinical trial of 7a-methyl-19- nortestosterone implants for possible use as a long acting contraceptive for men. J Clin Endocrinol Metab88:5232-5239
94. Waites GMH (2003) Development of methods of male contraception: the impact of the World Health Organization Task Force. Fertil Steril80:1-15
95. Walton MJ, Kumar N, Baird DT, Ludlow H, Anderson RA (2007) 7alpha-methyl-19-nortestosterone (MENT) vs testosterone incombination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl28:679-688
96. Wang C, Yeung KK (1980) Use of lowdosage oral cyproterone acetate as a male contraceptive. Contraception21:245
97. Wang C, Wang XH, Nelson AL (2006) Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. J Clin Endocrinol Metab91:460-470
98. Wang C, Cui YG, Wang XH, Jia Y, Sinha Hikim A, Lue YH, Tong JS, Qian LX, Sha JH, Zhou ZM, Hull L, Leung A, Swerdloff RS (2007) Transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis. J Clin Endocrinol Metab92:3292-3304
99. Weinbauer GF, Nieschlag E (1996) The Leydig cell as a target for male contraception. In: Payne AH, Hardy MP, Russell LD (eds) The Leydig Cell. Cache River Press, Vienna, IL, pp 629-662
100. Weinbauer GF, Surmann FJ, Nieschlag E (1987) Suppression of spermatogenesis in a nonhuman primate (Macaca fascicularis) by concomitant gonadotropinreleasing hormone (GnRH) antagonist and testosterone treatment. Acta Endocrinol114:138-146
101. Weinbauer GF, Khurshid S, Fingscheidt U, Nieschlag E (1989) Sustained inhibition of sperm production and inhibin secretion induced by a gonadotropinreleasing hormone antagonist and delayed testosterone substitution in non-human primates (Macaca fascicularis). J Endocrinol123:303-310
102. Weinbauer GF, Limberger A, Behre HM, Nieschlag E (1994) Can testosterone alone maintain the gonadotropin-releasing hormone antagonist-induced suppression of spermatogenesis in the nonhuman primate? J Endocrinol142:485-495
103. Weinbauer GF, Schlatt S, Walter V, Nieschlag E (2001) Testosteroneinduced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (Macaca fascicularis). J Endocrinol168:25-38
104. Weston GC, Schlipalius ML, Bhuinneain MN, Vollenhoven BJ (2002) Will Australian men use male hormonal contraception? A survey of a postpartum population. Med J Aust76:204-205
105. WHO (1972-1995) Special Programme of Research, Development andResearch Training in Human Reproduction, Annual and BiannualReports. World Health Organization, Geneva
106. WHO Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet336:955-959
107. WHO Task Force on Methods for the Regulation of Male Fertility (1993) Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril60:1062-1068
108. WHO Task Force on Methods for the Regulation of Male Fertility (1995) Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. Int J Androl18:157-165
109. WHO Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril65:821-829
110. Wu FC, Aitken RJ (1989) Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril51:691-698
111. Wu FCW, Balasubramanian R, Mulders TMT, Coelingh-Bennink HJT (1999) Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocr Metab84:12-122
112. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab84:3642-3647
113. Zhang L, Shal IH, Liu Y, Vogelsong KM, Zhang L (2006) The acceptability of an injectable, once-a-month male contraceptive in China. Contraception73:548-553
114. Zitzmann M, Junker R, Kamischke A, Nieschlag E (2002) Contraceptive steroids influence the hemostatic activation state in healthy men. J Androl23:503-511